Shamis & Gentile, P.A. is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (Nasdaq: MREO). Impacted investors are advised to contact the firm now.
The investigation concerns whether Mereo and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The investigation focuses on representations made by Mereo between June 11, 2024 and July 9, 2025. Throughout this period, the Company and its partners issued statements regarding the progress and efficacy of the Phase 3 Orbit study for setrusumab. However, on July 9, 2025, Mereo and Ultragenyx announced that the Orbit trial would proceed to a final analysis at year-end, following the Data Monitoring Committee’s recommendation to continue the study. This announcement seemingly contradicted prior expectations of an early trial stop based on interim efficacy.
On this news, Mereo’s stock price fell approximately 42% on July 10, 2025, closing at its lowest share price in months.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
